Alamar Biosciences Inc. Common Stock (ALMR)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary of paying up for promise, and Alamar is a promise stock. It sells proteomics instruments, consumables, and services built on NULISA and the ARGO system. The top line is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $29.4M, up from $16.2M in fiscal Q2 2025. Fiscal Q1 2026 revenue was $26.0M versus $13.1M in fiscal Q1 2025. That is real growth. But growth without profits is not yet a business I can value with confidence. In fiscal Q2 2026 net income was -$13.2M, worse than -$7.0M a year earlier. In fiscal Q1 2026 net income was -$21.3M, worse than -$7.7M. Trailing free cash flow was -$63.2M, a -3.9% FCF yield on the $1.6B market cap. FairStock calculates P/B of 5.22, ROE of -33.58%, ROCE of -13.53%, and a negative P/E of -32.67 at the 2026-10-13 close. The balance sheet shows low leverage, D/E 0.16, and Altman Z 12.70, but no durable moat is proven yet. Piotroski 5/9 and FairStock Score 20/100 suggest mediocre financial quality. The Lynch category is none because only 0 years of filed results exist and three are needed. I see a promising platform but no margin of safety. The price already discounts much success, while losses are widening. I would want evidence of operating leverage, recurring consumable pull, and a path to cash profits before calling this a value opportunity.

In plain English: Alamar Biosciences makes laboratory tools and services that test proteins to help detect diseases. Sales are growing quickly, but the company is still losing money and burning cash. At the recent stock price, the business looks expensive relative to its profits because there are no profits yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer